Core Viewpoint - The article highlights the current condition and ongoing efforts of ALS patient Cai Lei, emphasizing his determination to combat the disease through research and collaboration with AI technology [1][4][5]. Group 1: Current Condition - Cai Lei has lost his ability to speak and has limited mobility, relying on a communication device to type using eye control [1][3]. - His physical condition has been stable for several months, although he requires frequent breaks during work due to fatigue [3]. Group 2: Research and Collaboration - Cai Lei's research team has engaged in 14 online meetings with international experts on various topics related to ALS treatment from July 26 to August 31 [3]. - He has reached out to AI companies, including DeepMind, to explore potential collaborations for tackling ALS, which has garnered positive responses [4][5]. Group 3: Funding and Support - Over the past 1 year and 8 months, Cai Lei's team has donated over 50 million yuan to research, with plans to continue funding numerous projects in various scientific fields [6]. - Cai Lei initiated the "Chunlei" plan, committing 10 million yuan to support ALS research, with additional personal contributions planned [8]. Group 4: Achievements and Recognition - In 2024, under various support, Cai Lei's team successfully advanced 10 drug pipelines into clinical stages and established a support network for 15,000 ALS patients [9]. - He received the "National Self-Strength Model" title, which he views as recognition not only for himself but also for the broader ALS community [9].

Core Viewpoint - The article highlights the significant advancements in the treatment of Amyotrophic Lateral Sclerosis (ALS), particularly through the efforts of patient advocate Cai Lei, who emphasizes the role of Chinese technology, national support, and community solidarity in achieving breakthroughs in drug development for this previously untreatable disease [1][9]. Group 1: Patient Advocacy and Research Efforts - Cai Lei, diagnosed with ALS in 2019, has dedicated himself to combating the disease, unlike many who choose to give up [3][4]. - He has faced challenges in securing funding for research, often encountering rejections, but remains determined to continue his efforts [6]. - In 2024, with support from various sectors, his team successfully advanced 10 drug candidates into clinical stages [6]. Group 2: Community and Support Initiatives - The "Jianyu Mutual Aid Home," initiated by Cai Lei, has reached 15,000 ALS patients, providing crucial support [6]. - Approximately 1,000 patients have signed up to donate their bodies and spinal cord tissues for research, showcasing a strong community commitment to finding a cure [8]. Group 3: Clinical Developments and Future Prospects - A drug targeting specific genetic types of ALS has entered Phase I clinical trials, marking a significant milestone in treatment options [9]. - Despite the progress, Cai Lei's specific genetic condition is not included in the current breakthroughs, highlighting the ongoing challenges faced by many patients [10]. Group 4: Recognition and Technological Integration - Cai Lei received the title of "National Self-Reliance Model," which he views as recognition not just for himself but for the entire ALS community [12]. - The integration of artificial intelligence in ALS research has led to the identification of new treatment targets and potential drugs, indicating a promising direction for future therapies [14].